Drugs / Tomuzotuximab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03360734 | Nov 2017 → May 2020 | cancer | Glycotope GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01222637 | Aug 2010 → Aug 2012 | cancer | Glycotope GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02052960 | Feb 2014 → Aug 2017 | head and neck squamous cell carcinoma | Glycotope GmbH | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tomuzotuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03360734 ↗ |
| Known as | CetuGEX | “Tomuzotuximab (CetuGEX®) is an improved second-generation anti-epidermal growth factor receptor (EGFR) antibody” NCT03360734 ↗ |
| Action | Inhibit | “receptor blockade by the antibody” PMID 29464112 ↗ Feb 2018 |
| Modality | Monoclonal antibody | “Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR” NCT03360734 ↗ |
| Route | Intravenous | “after intravenous administration” NCT01222637 ↗ |
| Target | EGFR | “Tomuzotuximab (CetuGEX®) is an improved second-generation anti-epidermal growth factor receptor (EGFR) antibody” NCT03360734 ↗ |